The DEA's five controlled substance schedules rank drugs by their abuse potential and accepted medical use. Schedule I has the highest abuse potential and no accepted medical use; Schedule V has the lowest. The schedule your medication falls in dictates how your prescription is written, whether and how many times it can be refilled, and how your pharmacist and prescriber must handle it. Understanding the system helps you know what to expect at the pharmacy — and why certain medications require more paperwork than others.
DEA Drug Schedules Explained: What Schedules I–V Mean for Patients
You pick up a new prescription and notice the label says "CAUTION: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed." Or the pharmacist tells you they can only dispense a 30-day supply and that your doctor will need to write a new prescription each month — you can't call in a refill. Or you read news coverage about whether marijuana might be "rescheduled" and wonder what that actually means. All of these experiences trace back to the same source: the federal Controlled Substances Act and the five-tier drug scheduling system administered by the Drug Enforcement Administration.
The scheduling system is one of the most consequential pieces of pharmaceutical law for everyday patients, yet most people have only a vague sense of how it works. Is Xanax a Schedule II or IV? Does a Schedule III drug require a new prescription every month? Can your doctor prescribe psilocybin? What actually changes if marijuana is moved from Schedule I to Schedule III? These are practical, answerable questions — and the answers have real effects on how patients obtain, pay for, and use their medications.
This guide explains the entire system from the ground up: where it came from, what each schedule means in plain language, the specific rules that apply at the pharmacy, what is currently being debated about rescheduling, and practical answers to the questions patients most commonly ask.
The Controlled Substances Act: A Brief History
The legal framework governing controlled substances in the United States is the Comprehensive Drug Abuse Prevention and Control Act of 1970 — universally known as the Controlled Substances Act, or CSA. Signed into law by President Nixon on October 27, 1970, the CSA consolidated a patchwork of earlier federal drug laws into a single statute and established the scheduling system that remains in place today, largely unchanged in its fundamental structure.
The CSA was born out of a particular cultural and political moment. The late 1960s had seen an explosion in recreational drug use, from psychedelics and marijuana among counterculture communities to the proliferation of amphetamines and barbiturates dispensed liberally by physicians. At the same time, heroin addiction was devastating urban communities, and public concern about drug abuse was at a peak. Congress responded by creating a regulatory framework intended to balance the legitimate medical need for controlled substances against the risks of diversion and abuse.
The architects of the CSA established two lead federal agencies. The Food and Drug Administration was given authority over the scientific and medical evaluation of substances — assessing their pharmacology, abuse potential, and medical utility. The DEA (then the Bureau of Narcotics and Dangerous Drugs, reorganized into the DEA in 1973) was given enforcement authority and the administrative responsibility for maintaining the schedules. Today, the two agencies jointly evaluate substances: the FDA provides a scientific and medical evaluation, and the DEA makes the final scheduling determination, which is published in the Code of Federal Regulations.
The CSA did not create the idea of regulated narcotics — earlier laws, including the Harrison Narcotics Tax Act of 1914 and the Marihuana Tax Act of 1937, had regulated specific drugs through taxation and registration requirements. But the CSA unified these disparate approaches, created the five-schedule system, established criminal penalties for violations, and — crucially — created the administrative mechanism for adding, removing, or rescheduling substances over time as scientific evidence and medical consensus evolves.
How the Scheduling System Works: The Two Criteria
Every placement in the scheduling system is determined by the intersection of two factors: abuse potential and accepted medical use in treatment in the United States. A drug with high abuse potential and accepted medical use goes in Schedule II. A drug with high abuse potential and no accepted medical use goes in Schedule I. As abuse potential decreases and medical use becomes clearer, a substance moves down toward Schedules III, IV, and V.
The CSA defines eight factors that the DEA and FDA consider when evaluating a substance for scheduling:
- Its actual or relative potential for abuse
- Scientific evidence of its pharmacological effect, if known
- The state of current scientific knowledge regarding the drug or other substance
- Its history and current pattern of abuse
- The scope, duration, and significance of abuse
- What, if any, risk there is to the public health
- Its psychic or physiological dependence liability
- Whether the substance is an immediate precursor of an already-controlled substance
The word "abuse" in the CSA context has a specific regulatory meaning: use of a drug in a manner or amount that causes harm, or use in a manner that society does not sanction — including use for intoxication or recreational purposes rather than medical need. This definition is somewhat circular and has been criticized by pharmacologists and public health researchers, but it remains the operative standard.
Schedule-by-Schedule: The Complete Breakdown
| Schedule | Abuse Potential | Medical Use? | Refills Allowed | Rx Required? | Example Substances |
|---|---|---|---|---|---|
| Schedule I | Highest | None (federally) | N/A — not prescribable | Cannot be prescribed | Heroin, LSD, psilocybin, MDMA, marijuana (federal) |
| Schedule II | High | Yes, severe restrictions | No refills | Written/electronic Rx only | Oxycodone, fentanyl, morphine, Adderall, Ritalin, methadone, cocaine (medical) |
| Schedule III | Moderate | Yes | Up to 5 refills / 6 months | Written, oral, or electronic Rx | Buprenorphine, ketamine, testosterone, anabolic steroids, Tylenol with codeine |
| Schedule IV | Lower | Yes | Up to 5 refills / 6 months | Written, oral, or electronic Rx | Xanax, Valium, Ativan, Klonopin, Ambien, tramadol, carisoprodol |
| Schedule V | Lowest | Yes | Up to 5 refills / 6 months | Rx or OTC (state-dependent) | Cough preparations with small codeine amounts, pregabalin (Lyrica), lacosamide (Vimpat) |
Schedule I: The Highest Restriction Tier
Schedule I is the category that generates the most public debate, and for good reason: its defining criterion — "no currently accepted medical use in treatment in the United States" — is increasingly in tension with emerging science. To be in Schedule I, a substance must simultaneously have high abuse potential and no accepted medical use. That means a highly addictive drug with genuine therapeutic applications (like oxycodone or fentanyl) does not belong in Schedule I — it belongs in Schedule II. Schedule I is reserved for substances where the DEA and FDA jointly determine that there is no legitimate therapeutic application currently recognized in U.S. medicine.
The most prominent example, and the most contested one in contemporary policy debate, is marijuana (cannabis). Under federal law, marijuana has been Schedule I since the CSA was enacted in 1970. The DEA and FDA have consistently maintained — over multiple petitions, court challenges, and decades of state-level legalization — that the scientific evidence is insufficient to establish accepted medical use at the federal level, largely because the clinical trial evidence base was historically limited (due partly to the difficulty of conducting research on a Schedule I substance). This federal classification exists in direct conflict with state law in over 40 states that have enacted some form of medical marijuana program, and in more than two dozen states that have legalized recreational adult use. That conflict has profound implications discussed in detail below.
Psilocybin — the psychoactive compound in "magic mushrooms" — remains Schedule I federally despite a rapidly growing body of clinical evidence suggesting therapeutic potential in treatment-resistant depression, end-of-life anxiety, and addiction. The FDA has granted psilocybin "Breakthrough Therapy" designation for treatment-resistant depression, which does not change its scheduling but signals the agency believes it warrants expedited review. Several cities and states, including Oregon and Colorado, have moved to allow supervised therapeutic use at the state level — another example of the growing divergence between state action and federal scheduling.
MDMA (ecstasy) was the subject of a high-profile FDA advisory committee vote in 2024 in the context of PTSD treatment. The committee voted against recommending approval for MDMA-assisted psychotherapy, citing concerns about trial design, functional unblinding, and the risk-benefit profile in the studied populations. With FDA rejection, MDMA remains Schedule I. Research continues under Schedule I researcher registrations at several academic institutions.
Schedule II: High Potential, Strict Controls
Schedule II is where most of the opioids patients encounter in pain management and most of the stimulants prescribed for ADHD reside. The "no refills" rule is the most consequential practical difference from lower schedules. A patient on a long-term Schedule II medication — a patient with chronic pain taking an extended-release opioid, or an adult with ADHD on amphetamine salts — must obtain a new prescription from their prescriber every single fill cycle. Most states allow a 30-day supply per prescription, though some allow up to a 90-day supply in certain circumstances (particularly for ADHD medications, where some states have updated their rules).
The requirement for written or electronic prescriptions — no phone-in refills — is a deliberate anti-diversion measure. The DEA and Congress made a policy judgment that the abuse and diversion risk of Schedule II medications is high enough to require a verifiable paper or electronic trail for every dispensing event. Electronic prescribing for controlled substances (EPCS) is now widely available and in some states mandatory; it provides a digital record with prescriber authentication and is increasingly the standard for Schedule II medications.
Prescription Drug Monitoring Programs (PDMPs): Every state now operates a PDMP — a database that records every dispensed controlled substance prescription. Pharmacists and prescribers check the PDMP before dispensing or writing Schedule II prescriptions to identify patients receiving the same drug from multiple prescribers ("doctor shopping") or receiving combinations of drugs that represent diversion or overdose risk. PDMPs are linked between states through the PMP InterConnect network, so a prescription filled in one state is visible to providers in participating neighboring states.
Methamphetamine appears on Schedule II because there is an FDA-approved pharmaceutical formulation — brand name Desoxyn — indicated for obesity and ADHD. Pharmaceutical methamphetamine is chemically the same molecule as illicit methamphetamine but manufactured to pharmaceutical standards and dispensed in far lower strengths than typical street product. It is rarely prescribed because other options are generally preferred, but its medical use classification means it legally belongs in Schedule II rather than I. Similarly, cocaine is Schedule II because it retains legitimate use as a topical vasoconstrictor and local anesthetic in certain ear, nose, and throat surgical procedures.
Schedule III: Moderate Potential, More Flexible Prescribing
Schedule III is notable for housing buprenorphine — one of the most clinically significant medications in opioid use disorder treatment. Buprenorphine is a partial opioid agonist that reduces cravings and withdrawal symptoms without producing the full euphoric effect of drugs like heroin or oxycodone. As a Schedule III drug (in most formulations), buprenorphine can be prescribed by any DEA-registered practitioner — a significant policy expansion from prior rules that required a separate DEA waiver. This change, enacted through the Mainstreaming Addiction Treatment Act effective January 2023, dramatically expanded the pool of clinicians who can prescribe buprenorphine for opioid use disorder.
Ketamine's Schedule III placement reflects its decades of legitimate use as an anesthetic in surgical and emergency medicine settings, where it has an excellent safety profile when administered in controlled clinical environments. More recently, esketamine (Spravato), an intranasal formulation derived from ketamine, was FDA-approved for treatment-resistant depression — dispensed only in certified healthcare settings with observed administration and a monitoring period. Ketamine infusions for depression are not yet FDA-approved for that indication (they are used off-label), but the drug's Schedule III status does allow practitioners who are registered and trained to administer it in clinical infusion settings.
Anabolic steroids — including testosterone prescribed for hypogonadism or other clinical indications — are Schedule III. This places them in the same tier as ketamine and buprenorphine despite a very different risk profile, reflecting Congress's specific addition of anabolic steroids to Schedule III via the Anabolic Steroid Control Act of 1990 (and expanded in 2004), driven more by concerns about sports doping than by clinical harm considerations.
Schedule IV: Widely Prescribed, Lower but Real Abuse Potential
Schedule IV contains many of the most commonly prescribed controlled substances in American medicine. The benzodiazepines — alprazolam, diazepam, lorazepam, clonazepam, and others — are widely prescribed for anxiety disorders, panic disorder, and certain seizure conditions. The "Z-drugs" for insomnia — zolpidem (Ambien), eszopiclone (Lunesta), zaleplon (Sonata) — are also Schedule IV. Despite the "lower abuse potential" designation relative to Schedule III and II, benzodiazepines and Z-drugs carry real and clinically significant dependence and withdrawal risks. Benzodiazepine withdrawal can be life-threatening in cases of abrupt discontinuation after prolonged high-level use — analogous in some respects to alcohol withdrawal — and patients should never stop benzodiazepines abruptly without medical supervision.
Tramadol was added to Schedule IV in 2014 after post-market evidence accumulated demonstrating its abuse and dependence potential was higher than its original unscheduled status suggested. Carisoprodol (Soma), a muscle relaxant, was similarly added to Schedule IV in 2012 after evidence of diversion and abuse. These additions illustrate that scheduling is not static — post-market pharmacovigilance data can and does lead to rescheduling, both upward (more restrictive) and downward (less restrictive).
Tramadol occupies a pharmacologically unusual position: it acts partly as an opioid agonist and partly as a serotonin-norepinephrine reuptake inhibitor, and one of its metabolites (O-desmethyltramadol) is a more potent opioid agonist than the parent compound. Its classification in Schedule IV rather than Schedule II may seem surprising to clinicians familiar with its opioid properties, but it reflects a regulatory judgment about its overall abuse potential relative to traditional opioids — a judgment that some pharmacologists and pain management specialists have questioned.
Schedule V: The Lowest Tier — and Some May Be OTC
Schedule V is a diverse category that ranges from familiar cough preparations to specialty neurological medications. The inclusion of pregabalin (Lyrica) in Schedule V reflects post-approval data showing that some patients misuse it for its euphoric and sedating effects at higher-than-prescribed quantities — though this risk is lower than for benzodiazepines or opioids. In the United Kingdom and several European countries, pregabalin and gabapentin are controlled under their respective drug laws at a higher restriction level than in the U.S., reflecting concerns about diversion and abuse in those markets.
The OTC provision in Schedule V — which allows states to permit pharmacists to dispense certain Schedule V products without a prescription, subject to recordkeeping requirements — is rarely relevant to patients today, as most Schedule V medications that would be encountered in practice (pregabalin, lacosamide) require a prescription in virtually all states.
What Scheduling Means for Patients: The Practical Rules
Summary of key prescription rules by schedule:
Schedule I: Cannot be prescribed. Period.
Schedule II: New written/electronic prescription required for every fill. No refills. No phone-in except declared emergency with 7-day written follow-up. DEA tracking and PDMP reporting required.
Schedule III & IV: Up to 5 refills within 6 months. Can be called in by prescriber. Must still be tracked in PDMPs.
Schedule V: Same refill rules as III/IV. Some products may be dispensed without a prescription under state OTC rules.
Beyond prescriptions and refills, scheduling affects several other aspects of your experience as a patient.
Storage and security. The DEA does not directly mandate how patients store controlled substances at home, but practical guidance — and common sense — is important. Schedule II medications in particular should be stored in a secure location inaccessible to others, including children, teenagers, and visitors. Leftover or unused controlled substances should be disposed of properly: DEA-authorized collection sites (typically pharmacies), DEA National Take-Back events, or in-home disposal using FDA-recommended methods. Flushing certain medications is FDA-approved for some — but not all — controlled substances; check the FDA flush list for specific drugs.
Quantity limits and early refills. Most states and most pharmacy benefit managers impose quantity limits on controlled substance prescriptions — typically a 30-day supply for Schedule II drugs. Early refills (attempting to refill before the previous supply is exhausted) are flagged by PDMPs and often rejected by pharmacies. In an emergency — if medication is lost, stolen, or damaged — contact your prescriber and pharmacy immediately. Lost or stolen controlled substances typically require reporting to law enforcement and your prescriber to obtain a replacement.
Insurance coverage and prior authorization. Controlled substances, particularly opioids and stimulants, are often subject to prior authorization requirements from insurance plans, quantity limits, and step-therapy protocols. Insurance formulary status is distinct from DEA scheduling; a Schedule II medication may be covered without restriction on one plan and require prior authorization on another. Work with your prescriber and pharmacist to navigate these requirements, which exist alongside — and independently of — the federal scheduling rules.
How Drugs Get Scheduled and Rescheduled
The scheduling process can be initiated in three ways: by a petition from any interested party (including drug companies, advocacy organizations, individual researchers, or state governments); by direction from the Secretary of Health and Human Services; or by the DEA on its own initiative. Once a petition is received or a proceeding is initiated, the process unfolds through several stages.
First, the DEA requests a scientific and medical evaluation from the FDA. The FDA's evaluation addresses the drug's chemistry, pharmacology, abuse potential, clinical data, international scheduling status, and whether there is accepted medical use in treatment in the United States. The FDA provides this evaluation as a recommendation to the DEA.
The DEA then makes its own scheduling determination — the FDA's recommendation is not binding, though in practice the DEA rarely diverges from it substantially. If the DEA proposes to schedule or reschedule a drug, it publishes a proposed rule in the Federal Register, opens a public comment period, and may hold a hearing. After reviewing all evidence and comments, the DEA publishes a final scheduling rule, which is codified in the Code of Federal Regulations and takes effect as binding law.
This process can take years — often three to five years from petition to final rule, and longer for contentious substances. Emergency scheduling is also possible for substances presenting imminent hazard to public safety; the DEA can temporarily place a substance in Schedule I for up to two years (with a one-year extension) without the full rulemaking process. This emergency scheduling authority has been used extensively for synthetic drug analogs, designer drugs, and fentanyl analogs.
Recent and Ongoing Rescheduling Controversies
Marijuana: The Schedule I–III Proposal
In August 2023, the U.S. Department of Health and Human Services formally recommended to the DEA that marijuana be rescheduled from Schedule I to Schedule III — an extraordinary reversal of the longstanding federal position that cannabis has no accepted medical use. The HHS recommendation followed an extensive FDA scientific review and represented the first time in history that HHS had recommended a lower scheduling designation for marijuana.
As of 2026, the DEA rulemaking process on marijuana rescheduling remains ongoing, with the formal proposed rule, public comment period, and administrative hearings having been conducted. A final rule has not yet been published. The practical consequences of a move to Schedule III would be significant but more limited than many advocates hope: marijuana would remain a federally controlled substance, interstate commerce would still be prohibited, and patients in states without medical marijuana laws would see little change. However, cannabis businesses operating legally under state law would gain a critical benefit: under Section 280E of the Internal Revenue Code, businesses that "traffic" in Schedule I or II substances cannot deduct ordinary business expenses for federal tax purposes — a provision that has cost legal cannabis companies hundreds of millions in effective additional taxes. Schedule III would remove this burden. Research access would also expand meaningfully.
Rescheduling to Schedule III would not legalize marijuana under federal law, would not require states to permit its use, and would not change the conflict between federal prohibition and state legalization schemes. It would be a significant regulatory shift, but not the federal legalization that some news coverage implies.
State vs. Federal Conflict: The Marijuana Paradox
The tension between federal Schedule I status and widespread state legalization creates a legal patchwork that has direct, practical consequences for patients. Under the Supremacy Clause of the U.S. Constitution, federal law supersedes state law — but the federal government has chosen not to prosecute individuals complying with state marijuana laws in states that have legalized it. This "Cole Memo" approach (formalized in 2013, rescinded in 2018, and effectively reinstated in practice) means that federal non-enforcement policy, not federal legalization, is what allows state-legal marijuana businesses and patients to operate.
Practically, this means: patients using state-legal medical marijuana cannot legally purchase a federally regulated firearm — checking "yes" to marijuana use on the ATF Form 4473 results in a denial, and checking "no" while using marijuana is a federal felony. Federal employees and employees of federal contractors subject to drug testing can be terminated for marijuana use even in legal states. Patients traveling through states that have not legalized marijuana with marijuana purchased legally in another state may violate both state and federal law during transit. Banking for cannabis businesses remains complicated because federally regulated financial institutions technically face drug trafficking exposure. Patients should understand that state legalization does not create federal authorization.
Kratom: The Pending Question
Kratom — a botanical product from the Southeast Asian plant Mitragyna speciosa — contains mitragynine and 7-hydroxymitragynine, alkaloids that interact with opioid receptors. The DEA attempted to emergency-schedule kratom as a Schedule I substance in 2016, but withdrew the notice after an unprecedented public response and Congressional opposition. Kratom currently remains unscheduled at the federal level, though several states and localities have banned it. The DEA and FDA have continued to issue warnings about kratom's risks, including dependence, withdrawal, and interactions with other substances. The scheduling status of kratom — and whether it will be added to the CSA schedules — remains an active, unresolved regulatory question.
Fentanyl Analogs: Scheduling by Category
The proliferation of illicit fentanyl analogs — chemically modified fentanyl derivatives designed to evade scheduling by altering the molecular structure slightly — prompted Congress to act through the Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act and, subsequently, the FENTANYL Results Act. Under current law, fentanyl analogs are subject to temporary Schedule I scheduling and Congress has repeatedly extended the authority to schedule them categorically, rather than requiring the DEA to schedule each new variant individually as it appears. This approach attempts to address the "whack-a-mole" problem of analog scheduling, where illicit chemists create new variants faster than the traditional scheduling process can respond.
If You Have a Controlled Substance Without a Prescription
⚠ LEGAL WARNING: Possessing a controlled substance (Schedule II through V) without a valid prescription is a federal crime, and in most states a state crime, regardless of why you have it or how you obtained it. Sharing, selling, or giving a controlled substance to another person — even a family member who takes the same medication — is federal drug distribution, which carries far more serious penalties than simple possession. Penalties escalate dramatically for Schedule I and II substances, for quantities above threshold amounts, and for repeat offenses. If you find unidentified medications, you can use PillID's pill identifier to determine what they are, but consult legal counsel before taking any other action.
Unlawful possession of a Schedule I or II controlled substance at the federal level is a misdemeanor for simple possession of small amounts (up to 1 year imprisonment and fines for a first offense) escalating to felonies for larger quantities, distribution, or repeat offenses. State penalties vary considerably — some states have decriminalized personal possession of small amounts of certain substances, while others maintain mandatory minimum sentences. Federal sentencing for drug trafficking is subject to the Sentencing Guidelines and mandatory minimums that can result in multi-year sentences even for non-violent first offenses.
The practical message for patients: always keep controlled substance medications in their original pharmacy-labeled containers, always bring proof of prescription when traveling, and never share medications — even to help a friend or family member in pain. The legal exposure is real and disproportionate to the impulse to help.
Found an unknown pill? Identify any tablet or capsule by imprint, color, and shape.
Identify a Pill on PillIDFrequently Asked Questions
Can I travel with Schedule II medications?
Domestically, yes — but carry Schedule II medications in their original pharmacy-labeled container and bring a copy of your prescription or a letter from your prescribing physician. The TSA does not require you to declare prescription medications, but having documentation is strongly advisable and will resolve any questions from law enforcement or security personnel. For international travel, rules vary dramatically by country — medications that are legal in the United States may be controlled, prohibited, or require pre-authorization abroad. Opioids, stimulants (amphetamines, methylphenidate), and benzodiazepines are commonly subject to strict rules in many countries. Contact the embassy or consulate of each country you plan to enter well in advance of travel, and some countries require a translated prescription or an import permit. Carry only what is necessary for your travel period — excessive quantities raise additional questions regardless of legitimacy.
What is a DEA number?
A DEA registration number is a unique identifier assigned by the Drug Enforcement Administration to practitioners, pharmacies, researchers, manufacturers, and distributors authorized to handle controlled substances. For prescribers, the DEA number takes the form of two letters followed by seven digits — for example, AB1234563. The first letter indicates the type of registrant (A or B for physicians and dentists, C for practitioners such as mid-level providers, etc.), the second letter is the first letter of the registrant's last name, and the remaining seven digits include a checksum built into the numbering system that allows pharmacists to verify authenticity. Pharmacies verify DEA numbers on every Schedule II through V prescription to confirm the prescriber is lawfully registered to prescribe that class of controlled substance. DEA registrations are specific to the individual practitioner and the practice location; they cannot be borrowed, transferred, or used by an unauthorized person. Practitioners must renew their DEA registration every three years and must comply with DEA regulations regarding recordkeeping and security for all controlled substances they handle.
Can a doctor prescribe Schedule I drugs?
Generally no — the inability to prescribe Schedule I substances is the defining characteristic of the classification. Schedule I drugs are deemed to have no currently accepted medical use in treatment in the United States, which by definition precludes standard prescribing. A practitioner with a standard DEA registration has no authority to write prescriptions for Schedule I substances. The narrow exception is research: the DEA issues Schedule I researcher registrations to scientists and institutions who are conducting approved research studies involving Schedule I substances. These registrations permit possession and use of those substances only within the bounds of the approved research protocol, not for general patient treatment. Clinical trials investigating psilocybin for depression, MDMA for PTSD, and other Schedule I substances operate under these research registrations. In states that have enacted psilocybin therapeutic access programs (Oregon, Colorado), practitioners operate under state regulatory frameworks that are technically in conflict with federal law — similar to the marijuana situation — and do not confer federal authorization.
What happens if I lose my Schedule II prescription?
A lost or stolen Schedule II prescription cannot simply be reprinted and is not refillable at the pharmacy. You will need to contact your prescribing physician or their office to explain the situation and request a new prescription. Because Schedule II prescriptions are tracked through PDMPs and cannot be called in routinely, your provider will typically need to issue a new written or electronic prescription. If your medication itself is lost or stolen (not just the prescription paper), report it to local law enforcement as this documentation may be needed when you request a replacement from your prescriber. Some states' PDMP records can help verify your prescription history. Electronic prescriptions for controlled substances reduce this problem — there is no paper that can be lost, stolen, or altered, and the electronic record remains accessible to your provider and pharmacy.
How do I know if my medication is a controlled substance?
Every controlled substance dispensed at a U.S. pharmacy must have its schedule indicated on the prescription container label — look for a "C" with a Roman numeral inside it (C-II, C-III, C-IV, or C-V). The FDA-approved drug label (the prescribing information or package insert) also lists the schedule prominently in the "Drug Abuse and Dependence" section. You can search the DEA's Controlled Substances database at dea.gov for any drug name, and the FDA's DailyMed at dailymed.nlm.nih.gov provides complete prescribing information including schedule status. PillID's drug database and pill identifier display schedule information for identified medications. If you are unsure about a specific product, your pharmacist is the fastest authoritative source — they deal with scheduling questions routinely and can immediately tell you a drug's status and what the prescribing rules are for your state.
Can pharmacists call in a Schedule II prescription?
No — pharmacists do not "call in" prescriptions to themselves. The relevant question is whether prescribers can phone in a Schedule II prescription to a pharmacy, and the answer is: not under normal circumstances. Schedule II prescriptions must be issued as written (paper) or electronic prescriptions. The DEA allows a narrow emergency exception: if a practitioner determines that an immediate Schedule II prescription is needed and a written prescription cannot be provided at that moment, they may telephone the prescription to the pharmacy — but the quantity is limited to the emergency supply needed, and the prescriber must deliver a written or electronic prescription to the pharmacy within seven days. Failure to provide the written follow-up is a DEA violation. Electronic prescribing for controlled substances (EPCS), where the prescriber sends a digitally authenticated electronic prescription directly to the pharmacy, is distinct from phoning in a prescription and is fully permissible for all schedules.